

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
19215

In Re Application Of: Gail Petuna Risbridger, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/551,352	October 4, 2006	Catherine Joyce	23389	1642	6430

Title:

**DIAGNOSIS OF ADVANCED CANCER**



Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19215

In Re Application of: Gail Petuna Risbridger, et al.

Application No.

10/551,352

Filing Date

October 4, 2007

Examiner

Catherine Joyce

Customer No.

23389

Group Art Unit

1642

Confirmation No.

6430

Title:

DIAGNOSIS OF ADVANCED CANCER

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

## Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 10, 2007

(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Dated: September 10, 2007


Xiaochun Zhu  
Registration No. 56,311  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
19215

In Re Application Of: Gail Petuna Risbridger, et al.



Application No. 10/551,352	Filing Date October 4, 2006	Examiner Catherine Joyce	Customer No. 23389	Group Art Unit 1642	Confirmation No. 6430
-------------------------------	--------------------------------	-----------------------------	-----------------------	------------------------	--------------------------

Title:

**DIAGNOSIS OF ADVANCED CANCER**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19215

In Re Application of: Gail Petuna Risbridger, et al.

Application No.

10/551,352

Filing Date

October 4, 2006

Examiner

Catherine Joyce

Customer No.

23389

Group Art Unit

1642

Confirmation No.

6430

Title:

DIAGNOSIS OF ADVANCED CANCER

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.****Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 10, 2007

(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Dated: September 10, 2007

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy &amp; Presser, P.C.

400 Garden City Plaza, Suite 300

Garden City, New York 11530

516-742-4343

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Gail Petuna Risbridger, et al. **Examiner:** Catherine Joyce  
**Serial No.:** 10/551,352 **Art Unit:** 1642  
**Filed:** October 4, 2006 **Docket:** 19215  
**For:** DIAGNOSIS OF ADVANCED CANCER **Dated:** September 10, 2007

**Confirmation No.:** 6430

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Australian Patent Application No. 2001-10078 B2, published April 30, 2001 (abstract), corresponding to PCT International Publication No. WO 01/29079 A1, published April 26, 2001;
2. Derwent Accession No. 2001-308476 (abstract only);
3. Risbridger G.P., "Recent Progress in Our Understanding of Inhibin in the Prostate Gland", *Journal of Endocrinology* 157(1):1-4 (1998);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 10, 2007


  
Xiaochun Zhu

4. Mellor S.L. et al., "Loss of the Expression and Localization of Inhibin  $\alpha$ -Subunit in High Grade Prostate Cancer", *Journal of Clinical Endocrinology and Metabolism* 83(3):969-975 (1998);
5. United States Patent Application Publication No. 2003/235820 A1, published December 25, 2003 to Mack et al.;
6. Risbridger G.P. et al., "Elevated Expression of Inhibin  $\alpha$  in Prostate Cancer", *The Journal of Urology* 171(1):192-196 (2004);
7. PCT International Publication No. WO 95/032431 A1, published November 30, 1995;
8. PCT International Publication No. WO 87/05702 A1, published September 24, 1987;
9. PCT International Publication No. WO 01/29079 A1, published April 26, 2001;
10. PCT International Publication No. WO 98/47526 A1, published October 29, 1998;
11. Sheth N.A. et al., "Circulating Levels of Inhibin in Cancer", *Neoplasma* 31(3):315-321 (1984);
12. Robertson D.M. et al., "Development of an Inhibin  $\alpha$  Subunit ELISA with Broad Specificity", *Molecular and Cellular Endocrinology* 180:79-86 (2001);
13. Betteridge A. et al., "A Two-Site Enzyme-Linked Immunosorbent Assay for Inhibin", *Biology of Reproduction* 45:748-754 (1991);
14. Frias, Jr. A.E. et al., "Preoperative Serum Level of Inhibin A is an Independent Prognostic Factor for the Survival of Postmenopausal Women with Epithelial Ovarian Carcinoma", *Cancer* 85(2):465-471 (1999);
15. Petraglia F. et al., "Inhibin B is the Major Form of Inhibin/Activin Family Secreted by Granulosa Cell Tumors", *Journal of Clinical Endocrinology and Metabolism* 83(3):1029-1032 (1998);
16. Robertson D.M. et al., "Inhibins/Activins as Diagnostic Markers for Ovarian Cancer", *Molecular and Cellular Endocrinology* 191:97-103 (2002); and
17. Dowling C.R. et al., "The Role of Inhibins and Activins in Prostate Cancer Pathogenesis", *Endocrine-Related Cancer* 7:243-256 (2000).

References 1-6 were cited in a Supplementary Partial Search Report dated November 7, 2006 received from the European Patent Office. References 4, 7-17 were cited in an International Search Report dated June 8, 2004 received from the Australian Patent Office. A copy of the International Search Report was previously submitted by Applicants on September 28, 2005. Applicants are submitting copies of Reference Nos. 1-4 and 6-17, as required by 37 C.F.R. §1.98 (a)(2)(i) and (ii), together with a copy of the Supplementary Partial European Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Xiaochun Zhu', written in a cursive style.

Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:dg

Form PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART  
CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

19215

Serial No.

10/551,352

Applicants

Gail Petuna Risbridger, et al.

Filing Date

October 4, 2006

Group Art Unit

1642

**U.S. PATENT PUBLICATION DOCUMENTS**

2003/235820 A1

12/25/03

Mack et al.

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUBCLASS

TRANSLATION

YES

NO

WO 95/032431 A1

11/30/95

PCT

✓

WO 87/05702 A1

9/24/87

PCT

✓

WO 01/29079 A1

4/26/01

PCT

✓

WO 98/47526 A1

10/29/98

PCT

✓

**OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

Australian Patent Application No. 2001-10078 B2, published April 30, 2001 (abstract), corresponding to PCT International Publication No. WO 01/29079 A1, published April 26, 2001

Derwent Accession No. 2001-308476 (abstract only)

Risbridger G.P., "Recent Progress in Our Understanding of Inhibin in the Prostate Gland", *Journal of Endocrinology* 157(1):1-4 (1998)Mellor S.L. et al., "Loss of the Expression and Localization of Inhibin  $\alpha$ -Subunit in High Grade Prostate Cancer", *Journal of Clinical Endocrinology and Metabolism* 83(3):969-975 (1998)Risbridger G.P. et al., "Elevated Expression of Inhibin  $\alpha$  in Prostate Cancer", *The Journal of Urology* 171(1):192-196 (2004)Sheth N.A. et al., "Circulating Levels of Inhibin in Cancer", *Neoplasia* 31(3):315-321 (1984)Robertson D.M. et al., "Development of an Inhibin  $\alpha$  Subunit ELISA with Broad Specificity", *Molecular and Cellular Endocrinology* 180:79-86 (2001)Betteridge A. et al., "A Two-Site Enzyme-Linked Immunosorbent Assay for Inhibin", *Biology of Reproduction* 45:748-754 (1991)Frias, Jr. A.E. et al., "Preoperative Serum Level of Inhibin A is an Independent Prognostic Factor for the Survival of Postmenopausal Women with Epithelial Ovarian Carcinoma", *Cancer* 85(2):465-471 (1999)Petraglia F. et al., "Inhibin B is the Major Form of Inhibin/Activin Family Secreted by Granulosa Cell Tumors", *Journal of Clinical Endocrinology and Metabolism* 83(3):1029-1032 (1998)Robertson D.M. et al., "Inhibins/Activins as Diagnostic Markers for Ovarian Cancer", *Molecular and Cellular Endocrinology* 191:97-103 (2002)Dowling C.R. et al., "The Role of Inhibins and Activins in Prostate Cancer Pathogenesis", *Endocrine-Related Cancer* 7:243-256 (2000)

EXAMINER

/Minh Tam Davis/ (11/03/2008)

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.